J. Colombel
Genetics · 2001–2020
A researcher in the Science corpus: 36 papers; trusts 4 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 250 citations into it; #4,239 of 6,854 by trust here, #97 by citations
- Epidemiology — 149 citations into it
- Rheumatology — 69 citations into it
Whom J. Colombel trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. Colombel overall
Papers from J. Colombel's perspective
Ordered by how strongly the researchers J. Colombel trusts endorse each paper. Same corpus, a different order for every researcher.
- Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. (Gastroenterology)
- The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (Gastroenterology)
- Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (Canadian journal of gastroenterology = Journal canadien de gastroenterologie)
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease (Nature Genetics)
- The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (Gastroenterology)
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. (Arthritis & Rheumatism)
- A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease (Nature)
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. (The Lancet)
- Infliximab maintenance therapy for fistulizing Crohn's disease. (New England Journal of Medicine)
- Identifying Relationships among Genomic Disease Regions: Predicting Genes at Pathogenic SNP Associations and Rare Deletions (PLoS Genetics)
Their papers
- High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. (2004) — 1,551 citations
- Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (2011) — 1,319 citations
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020) — 2,231 citations
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020) — 633 citations
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. (2017) — 756 citations
- Crohn's disease (2017) — 1,297 citations
- Ulcerative colitis (2017) — 1,593 citations
- Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. (2016) — 887 citations
- Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016) — 662 citations
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) — 1,455 citations
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) — 763 citations
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) — 692 citations
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) — 920 citations
- Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. (2014) — 718 citations
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) — 2,298 citations
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) — 2,088 citations
- Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. (2012) — 801 citations
- Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. (2012) — 623 citations
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. (2012) — 890 citations
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. (2012) — 1,275 citations